Last week’s top gainer was Amedica, followed by Nymox Pharmaceutical, Clovis Oncology, Cellectar Biosciences and Adamis Pharmaceuticals.

The NASDAQ Biotechnology index (INDEXNASDAQ:NBI) has had a tough week. With news of Mylan increasing the price on the Epipen and the subsequent consumer backlash, the NASDAQ Biotechnology Index recorded its biggest one-day drop since June 24 on Wednesday, August 24. As of Friday, the index was down by 2.73 percent with 2,983.92 points.

Despite that, these five companies recorded gains above 30 percent: Amedica Corp. (NASDAQ: AMDA), Nymox Pharmaceutical (NASDAQ:NYMX), Clovis Oncology (NASDAQ: CLVS), Cellectar Biosciences (NASDAQ:CLRBZ), and Adamis Pharmaceuticals (NASDAQ:ADMP).

Amedica Corp. (NASDAQ:AMDA)

Amedica manufactures medical grade silicon nitride, with a focus on development and application of interbody implants for hip and knee arthroplasty, as well as dental applications. Last week, America announced clearance from the US Food and Drug Administration on the company’s expanded Valeo® II Lateral Lumbar sizes.
As last week’s top gainer, Amedica gained 57.81 percent over the five-day trading period, and finished at $1.01 per share.

Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox is currently in Phase 3 trials in the US for fexapotide, a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH). Fexapotide is currently in the final stages of development.
Nymox gained 51.63 percent over the five-day trading period and finished at $3.73 per share.

Clovis Oncology (NASDAQ:CLVS)

Acquiring, developing and commercializing innovative anti-cancer agents in the US, Europe and additional international markets is the core of Clovis Oncology. Last week, Clovis announced acceptance of the US Food and Drug Administration of the New Drug Application (NDA) for accelerated approval of rucaparib, a drug for the treatment of advanced mutant BRCA ovarian cancer.
Clovis gained 34.20 percent over the five-day trading period and finished $23.15 per share.

Cellectar Biosciences (NASDAQ:CLRBZ)

Cellectar Biosciences is focused on cancer-targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. The company recently announced that it ended the second quarter with $7.9 million in cash and cash equivalents.
Cellectar Biosciences gained 31.67 percent over the five-day trading period and finished $0.79 per share.

Adamis Pharmaceuticals (NASDAQ:ADMP)

Adamis Pharmaceuticals is focused on developing and commercializing products for respiratory disease and allergy therapies. Currently, products being developed are the Epinephrine Injection PFS syringe product for the treatment of anaphylaxis, PC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-2000 for the treatment of bronchospasms.
Adamis Pharmaceuticals gained 30.94 percent over the five-day trading period, and finished $3.47 per share.
Data for 5 Top NASDAQ Stocks articles is retrieved each Friday after market close using The Globe and Mail’s market data filter. Only companies with a market capitalization greater than $10 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.
Securities Disclosure: I, Pia Rivera, hold no direct investment interest in any company mentioned in this article.


S&P 5003821.55-78.56


Heating Oil4.10-0.02
Natural Gas6.51+0.01